Novartis Ag (NVSEF) Return on Sales (2009 - 2025)

Novartis Ag has disclosed Return on Sales across 15 years of filings, most recently posting 0.0% for Q2 2025.

• Return on Sales for Q2 2025 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Sales came in at 0.0% for Q2 2025 at Novartis Ag, up from 0.0% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.03% in Q3 2021 to a low of 0.0% in Q2 2023.
• The 5-year median for Return on Sales is 0.0% (2024), against an average of 0.01%.
• Peak annual rise in Return on Sales reached 1 bps in 2021, while the deepest fall reached 20 bps in 2021.
• Novartis Ag's Return on Sales stood at 0.0% in 2021, then soared by 153 bps to 0.01% in 2022, then tumbled by 99 bps to 0.0% in 2023, then soared by 3251 bps to 0.0% in 2024, then gained by 13 bps to 0.0% in 2025.
• The last three Return on Sales figures came in at 0.0% (Q2 2025), 0.0% (Q4 2024), and 0.0% (Q2 2024), per Business Quant data.